Nasalferon granted sanitary registration for the treatment of acute respiratory infections 

The final approval of Nasalferon, a nasal spray that is easy for the public to use, was supported by the results of a Phase III clinical trial that demonstrated its antiviral effect, efficacy, and safety in controlling and improving the symptoms of these diseases.
The research, conducted during 2025 in health areas of Old Havana, showed significant adherence to the protocol and confirmed the product's ability to completely resolve respiratory symptoms, according to information provided by its developers.
According to the CIGB, Nasalferon is a nasal drop formulation whose active ingredient is recombinant human alpha 2b interferon, a molecule that has been used in different pharmaceutical forms and various therapeutic niches.
The drug already had conditional sanitary registration for the prophylaxis of SARS-CoV-2 infection, the virus that causes COVID-19, and now its indication has been expanded to include acute respiratory infections in general.
With this new registration, the medication is now being distributed in community pharmacies, where the public can obtain it with a prescription. Its retail price has been set at 172.50 CUP per 2 ml bottle.
As part of future projections, after demonstrating its safety and efficacy in the adult population, the CIGB research team plans to design new studies to involve pediatric patients, so that children can also benefit from this medication. With stable production by the Cuban biotechnology industry, Nasalferon is consolidating itself as another therapeutic alternative for acute respiratory illnesses available to the population.